Two major studies support the use of GLP‐1 agonists in the management and treatment of obesity: the SCALE study with liraglutide at a dose of 3 mg/day21 and the STEP study with semaglutide at a dose of 2.4 mg/week, which demonstrated clear benefits in weight loss in obese patients, with weight loss ranging from 8% to 20%.22 Here, GLP1R is linked to obesity disorder.